Literature DB >> 10063996

Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation.

A Casonato1, A Steffan, E Pontara, A Zucchetto, C Rossi, L De Marco, A Girolami.   

Abstract

Thrombocytopenia is frequently reported in type 2B von Willebrand disease (vWD), and thought to be related to the abnormally high affinity of 2B von Willebrand factor (vWF) for platelet GPIb-IX. To gain an insight into the nature of this thrombocytopenia, we measured plasma glycocalicin (GC) levels (as a marker of platelet turnover), and platelet surface expression of the alpha granule protein P-selectin (as a marker of platelet activation) in 9 patients with type 2B vWD before, and in 4 patients also following the infusion of 1-desamino-8-d-arginine vasopressin (DDAVP). Three patients presented a persistent decrease of platelet counts in the resting condition. GC levels were within the normal range, regardless of the platelet counts, in all but one patient who presented, on the other hand, a normal platelet count. Moreover, platelets expressed normal amounts of P-selectin on their surface, regardless of platelet counts. These findings suggest that the thrombocytopenia observed in type 2B vWD is not due to platelet activation and subsequent consumption in circulation. Despite a significant, albeit transient, decrease in platelet count, DDAVP did not induce an increase in plasma GC levels, nor enhance P-selectin expression. These observations indicate that the acute post-DDAVP thrombocytopenia in type 2B vWD is not related to platelet activation and consumption. We advance that the post-DDAVP 2B vWF is hemostatically more active, and able to induce agglutination but not aggregation of circulating platelets. This would explain both the prompt recovery of basal platelet counts after the post-DDAVP decrease, and the lack of reported thrombotic complications in this disorder. Therefore, even though 2B vWF is characterized by an enhanced affinity for the platelet surface, its binding to platelet GPIb-IX in the soluble phase is not able to induce true platelet aggregation: vWF thus appears to be mainly an adhesive protein, rather than an aggregating agent.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10063996

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  10 in total

Review 1.  Thrombotic and Hemorrhagic Conditions Due to a Gain of Function of Coagulation Proteins: A Special Type of Clotting Disorders.

Authors:  Antonio Girolami; Elisabetta Cosi; Silvia Ferrari; Annamaria Lombardi; Fabrizio Fabris
Journal:  Clin Appl Thromb Hemost       Date:  2017-08-04       Impact factor: 2.389

2.  Rapid discrimination of the phenotypic variants of von Willebrand disease.

Authors:  Jonathan C Roberts; Patti A Morateck; Pamela A Christopherson; Ke Yan; Raymond G Hoffmann; Joan Cox Gill; Robert R Montgomery
Journal:  Blood       Date:  2016-02-25       Impact factor: 22.113

Review 3.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2017-08-02       Impact factor: 22.113

4.  Enhanced Local Disorder in a Clinically Elusive von Willebrand Factor Provokes High-Affinity Platelet Clumping.

Authors:  Alexander Tischer; Venkata R Machha; Juan P Frontroth; Maria A Brehm; Tobias Obser; Reinhard Schneppenheim; Leland Mayne; S Walter Englander; Matthew Auton
Journal:  J Mol Biol       Date:  2017-05-19       Impact factor: 5.469

5.  The Von Willebrand Factor A1-Collagen III Interaction Is Independent of Conformation and Type 2 Von Willebrand Disease Phenotype.

Authors:  Venkata R Machha; Alexander Tischer; Laurie Moon-Tasson; Matthew Auton
Journal:  J Mol Biol       Date:  2016-11-24       Impact factor: 5.469

6.  Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets.

Authors:  Caterina Casari; David S Paul; Sophie Susen; Cécile Lavenu-Bombled; Annie Harroche; Raymond Piatt; Kathryn O Poe; Robert H Lee; Marijke Bryckaert; Olivier D Christophe; Peter J Lenting; Cécile V Denis; Wolfgang Bergmeier
Journal:  Blood Adv       Date:  2018-06-26

7.  Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia.

Authors:  Alessandra Casonato; Lisa Gallinaro; Maria Grazia Cattini; Elena Pontara; Roberto Padrini; Antonella Bertomoro; Viviana Daidone; Antonio Pagnan
Journal:  Haematologica       Date:  2010-03-19       Impact factor: 9.941

Review 8.  The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology.

Authors:  Mike A Laffan; Will Lester; James S O'Donnell; Andrew Will; Robert Campbell Tait; Anne Goodeve; Carolyn M Millar; David M Keeling
Journal:  Br J Haematol       Date:  2014-08-12       Impact factor: 6.998

9.  Type 2B von Willebrand disease with or without large multimers: A distinction of the two sides of the disorder is long overdue.

Authors:  Alessandra Casonato; Viviana Daidone; Eva Galletta; Antonella Bertomoro
Journal:  PLoS One       Date:  2017-06-22       Impact factor: 3.240

Review 10.  Von Willebrand's disease: case report and review of literature.

Authors:  Hanae Echahdi; Brahim El Hasbaoui; Mohamed El Khorassani; Aomar Agadr; Mohamed Khattab
Journal:  Pan Afr Med J       Date:  2017-06-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.